REFERENCES

1. Mamkin I, Sood N, Ramanan SV. Taenia solium neurocysticercosis. N Engl J Med 2007;357:1666-7.

2. Osvaldo MT, Newton SO, Pierina SB, Jose EL, Vera LL. Medical management of neurocycsticercosis. Expert Opin Pharmacother 2011;12:2845-56.

3. Singh G, Burneo JG, Sander JW. From seizures to epilepsy and its substrates: neurocysticercosis. Epilepsia 2013;54:783-92.

4. Nash TE, Del Brutto OH, Butman JA, Corona T, Delgado-Escueta A, Duron RM, Evans CA, Gilman RH, Gonzalez AE, Loeb JA, Medina MT, Pietsch-Escueta S, Pretell EJ, Takayanagui OM, Theodore W, Tsang VC, Garcia HH. Calcific neurocysticercosis and epileptogenesis. Neurology 2004;62:1943-8.

5. Del Brutto OH. Diagnostic criteria for neurocysticercosis,revisited. Pathog Glob Health 2012;106:299-304.

6. Garcia HH, Gonzales I, Lescano AG, Bustos JA, Zimic M, Escalante D, Saavedra H, Gavidia M, Rodriguez L, Najar E, Umeres H, Pretell EJ; Cysticercosis Working Group in Peru. Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial. Lancet Infect Dis 2014;14:687-95.

7. Kalra V, Dua T, Kumar V. Efficacy of albendazole and short-course dexamethasone treatment in children with 1 or 2 ring-enhancing lesions of neurocysticercosis: a randomized controlled trial. J Pediar 2003;143:111-4.

8. Matthaiou DK, Panos G, Adamidi ES, Falagas ME. Albendazole versus praziquantel in the treatment of neurocysticercosis: a meta-analysis of comparative trials. PLoS Negl Trop Dis 2008;2:e194.

9. Gardenas G, Carrillo MR, Jung H, Sciutto E, Hernandez JL, Fleury A. Subarachnoidal neurocysticercosis non-reponsive to cysticidal drugs: a case series. BMC Neurol 2010;10:16.

10. Takayanagui OM. Therapy forneurocysticercosis. Expert Rev Neurother 2004;4:129-39.

11. Pretell EJ, Garcia HH, Gilman RH, Saavedra H, Martinez M; Cysticercosis Working Group in Peru. Failure of one-day praziquantel treatment in patients with multiple neurocysticerosis lesions. Clin Neurol Neurosurg 2001;103:175-7.